Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Global Health
Large Cap•9,052 Employees•IPO 2022
Current Price
₹1110.10
-1.6 (-0.14%)Updated
Today's Range
₹1101.60
₹1119.00
₹1110.10
52 Week Range
52W Low₹1010.00
52W High₹1456.50
₹1110.10
Downside9.91%
Upside31.20%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹31,539.86 Cr
Market Cap
Total market value of companyP/E Ratio
54.79
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
9.52
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹20.90
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.33%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
19.70%
ROCE
Return on Capital Employed. >15% is goodNet Margin
14.03%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
67.62%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
19.73%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
19.70%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
49.60%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.21
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹126.08
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
33.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Medanta demonstrates robust profitability with a 16.5% Return on Equity and a 19.70% Return on Capital Employed, showcasing efficient capital utilization. Its 24.3% Operating Profit Margin highlights strong operational efficiency.
- •The company exhibits impressive growth, with quarterly sales surging by 19.70% and quarterly profit by a substantial 49.60%. This indicates strong market traction and significant potential for sustained financial expansion.
Weaknesses
4 points- •Medanta's Price-to-Earnings (PE) ratio of 64.90 is relatively high, indicating a premium valuation. This could make the stock susceptible to corrections if future earnings growth does not meet elevated investor expectations.
- •The company's promoter holding stands at a relatively low 33.01% as of 2025-09-01. This lower stake might raise concerns about long-term corporate governance and could increase vulnerability to external market pressures.
Opportunities
3 points- •The robust growth of the healthcare sector, fueled by increasing health awareness, an aging population, and rising disposable incomes, presents significant expansion opportunities for Medanta in new markets.
- •Compared to larger peers, Medanta's market capitalization of ₹36,986 crore indicates substantial room for market share expansion. This allows for scaling operations and capturing a larger segment of the growing healthcare market.
Threats
4 points- •The highly competitive healthcare sector, with established players like Apollo Hospitals and Max Healthcare, poses a continuous threat to Medanta's market share and pricing power, potentially impacting future growth.
- •Potential changes in healthcare regulations, government policies, or pricing controls could significantly impact Medanta's operational costs and revenue streams, posing a notable risk to its profitability and stability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1153.67 | +₹43.57 | +3.92% |
| R3 | ₹1136.27 | +₹26.17 | +2.36% |
| R2 | ₹1127.63 | +₹17.53 | +1.58% |
| R1 | ₹1118.87 | +₹8.77 | +0.79% |
| PIVOT | ₹1110.23 | 0.13 | 0.01% |
| CURRENT | ₹1110.10 | - | - |
| S1 | ₹1066.67 | -₹43.43 | -3.91% |
| S2 | ₹1084.07 | -₹26.03 | -2.35% |
| S3 | ₹1092.83 | -₹17.27 | -1.56% |
| S4 | ₹1101.47 | -₹8.63 | -0.78% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-61.1% vs avg
0.48L
(06 Mar 2026)Delivery %+1.8% vs avg
54.2%
(06 Mar 2026)Avg Volume (20D)20-day average
1.22L
(06 Feb - 06 Mar)Avg Delivery %Trend ↑
52.4%
(06 Feb - 06 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Apollo Hospitals Enterprise Ltd
1.09L ₹ Cr
Best Profit Growth
Dr Agarwals Health Care Ltd
151.00 %
Highest Dividend Yield
Rainbow Childrens Medicare Ltd
0.51 %
Peer Comparison
| Company Name |
|---|
 Dr Agarwals Health Care Ltd |
 Apollo Hospitals Enterprise Ltd |
 Aster DM Healthcare Ltd |
 Fortis Healthcare Ltd |
 Healthcare Global Enterprises Ltd |
 Jupiter Life Line Hospitals Ltd |
 |
 Krishna Institute of Medical Sciences Ltd |
 Max Healthcare Institute Ltd |
 Narayana Hrudayalaya Ltd |
 Rainbow Childrens Medicare Ltd |
About
Global Health Ltd
Medanta, operating under Global Health Limited, is a prominent healthcare provider in India offering a comprehensive range of medical services. Their business model centers around a network of hospitals under the Medanta brand, delivering advanced medical treatments across numerous specialties. This wide-ranging approach allows them to cater to a broad spectrum of patient needs, from routine check-ups to complex, life-saving procedures.
The company's services span a vast array of medical disciplines. These include highly specialized areas such as cardiac and cancer care, neurosciences, liver and lung transplants, and bone marrow transplants. Alongside these advanced treatments, Medanta also provides a comprehensive suite of general medical services, encompassing digestive and hepatobiliary sciences, musculoskeletal disorders and orthopedics, renal care, and a wide range of surgical specialities including plastic, aesthetic and reconstructive surgery, ENT, and chest surgery. Furthermore, they offer substantial care for women's health, covering gynecology, obstetrics, and pediatric care.
Beyond direct patient care, Medanta's business extends to supporting services that enhance the patient experience and overall healthcare access. These ancillary services include advanced diagnostic and laboratory testing, convenient homecare and elder care options, and the utilization of telemedicine to expand reach. They also provide critical support services like a blood bank, e-ICU services, and air ambulance services for emergency situations. In addition, Medanta offers health plans to facilitate access to their services and operates in-house pharmacies for patient convenience.
In summary, Medanta's business model integrates advanced medical treatments with comprehensive support services to establish a robust and multifaceted healthcare system. Their focus on a wide range of specializations, coupled with their commitment to ancillary services, positions Medanta as a major player in the Indian healthcare market, providing a holistic approach to patient care and accessibility.
COMPANY FACTS - MEDANTA
Registered Address
Company Details
Group: Health Care Equipment & Services
Sector: Health Care
Industry: Health Care Providers & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 9,052
IPO Date: 16/11/2022
MANAGEMENT - MEDANTA
Dr. Naresh Trehan
Chairman of the Board, Managing Director
Mr. Pankaj Sahni
Group Chief Executive Officer, Whole Time Director
Mr. Yogesh Gupta
Chief Financial Officer
Mr. Manoj Gupta
Senior Vice President, Head - Human Resources
Mr. Saurabh Upadhyay
Senior Vice President, Head of Human Resources
Mr. Rajiv Sikka
Chief Information Officer
Mr. Rahul Ranjan
Compliance Officer, Company Secretary
Ms. Richa Singh
General Counsel
Dr. Sanjay Geed
Medical Director - Indore Hospital/Unit
Dr. Sanjeev Gupta
Medical Director - Medical Administration and Clinical Operations at Medanta - the Medicity, Gurugram
Mr. Bhuvander Kaul
Chief Procurement Officer
Mr. Vinodh Krishnankutty
Director - Nursing at Medanta - the Medicity, Gurugram
Investor Questions Answered
Global Health Ltd (MEDANTA) Stock FAQs
Get answers to the most common questions about Global Health Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Global Health Ltd (MEDANTA) is ₹1,110.1. Today, the stock has declined by ₹1.60 (0.14%), trading in a range of ₹1,101.6 to ₹1,119. The stock opened at ₹1,104.1 with a trading volume of 47,552 shares.
Global Health Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹31,539.86 crores, P/E ratio of 54.79, ROE of 7.33%, and ROCE of 19.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Global Health Ltd (MEDANTA) is ₹1,456.5, while the 52-week low is ₹1,010. Currently trading at ₹1,110.1, the stock is 22.4% away from its 52-week low and 23.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Global Health Ltd stock at ₹1,110.1 depends on multiple factors. The stock is currently trading with a P/E ratio of 54.79 and P/B ratio of N/A. Today's performance shows a loss of 0.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Global Health Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,110.1, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Global Health Ltd's key financial metrics include: P/E Ratio: 54.79, P/B Ratio: N/A, ROE: 7.33%, ROCE: 19.70%, Dividend Yield: 0.00%, EPS: ₹20.90, Book Value: ₹126.08, Debt-to-Equity: 0.21, and Current Ratio: N/A. The company's market cap stands at ₹31,539.86 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Global Health Ltd stock opened at ₹1,104.1 and is currently trading at ₹1,110.1, showing a decline of ₹1.60 (0.14%). The intraday high is ₹1,119 and low is ₹1,101.6. The trading volume stands at 47,552 shares, indicating moderate market participation today.
Global Health Ltd has a Price-to-Earnings (P/E) ratio of 54.79, which means investors are willing to pay ₹54.79 for every ₹1 of earnings. With an EPS of ₹20.90, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Global Health Ltd has a market capitalization of ₹31,539.86 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,110.1) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Global Health Ltd has a book value of ₹126.08 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,110.1, which is 780.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Global Health Ltd has a Return on Equity (ROE) of 7.33% and Return on Capital Employed (ROCE) of 19.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Global Health Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Global Health Ltd has a debt-to-equity ratio of 0.21, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Global Health Ltd has an Earnings Per Share (EPS) of ₹20.90, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,110.1 and P/E ratio of 54.79, investors are paying 54.79 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Global Health Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Global Health Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Global Health Ltd stock, consider: 1) Fundamental Analysis - Review P/E (54.79), ROE (7.33%), debt-to-equity (0.21), and growth rates. 2) Technical Analysis - Check 52-week range (₹1010.00 - ₹1456.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1110.10) with book value (₹126.08) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Global Health Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,110.1 is 55405x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Global Health Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1010.00 - ₹1456.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.21 indicates leverage. 4) Liquidity Risk - Based on trading volume of 47,552 shares. 5) Valuation Risk - P/E of 54.79 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Global Health Ltd operates in the industry with key metrics: P/E ratio of 54.79, ROE of 7.33%, market cap of ₹31,539.86 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.21), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Global Health Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,110.1, with a 52-week range of ₹1010.00 to ₹1456.50. Based on fundamentals like P/E (54.79), ROE (7.33%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Global Health Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1110.10. 2) Fundamental Deterioration - Declining ROE (currently 7.33%), increasing debt (D/E: 0.21), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Global Health Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu